Advertisement

Endocrine

, Volume 57, Issue 1, pp 98–107 | Cite as

Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses

  • Martina Rossi
  • Sabrina Lupo
  • Roberta Rossi
  • Paola Franceschetti
  • Giorgio Trasforini
  • Stefania Bruni
  • Federico Tagliati
  • Mattia Buratto
  • Giovanni Lanza
  • Luca Damiani
  • Ettore degli Uberti
  • Maria Chiara ZatelliEmail author
Original Article

Abstract

Indeterminate thyroid nodules include heterogeneous lesions that could benefit from a differential management. Our aim is to better define the management of the Bethesda System for Reporting Thyroid Cytopathology class III and IV nodules, by identifying cytological subcategories among Bethesda System for Reporting Thyroid Cytopathology class III associated with different clinical risk, by means of ultrasound, repeated FNAB, and BRAFV600E molecular analysis. We also evaluated the outcome of nodules not operated, over a 5-year follow-up. Out of 460 nodules (269 Bethesda System for Reporting Thyroid Cytopathology class III and 191 Bethesda System for Reporting Thyroid Cytopathology class IV), 344 were operated on surgical group and 116 followed-up conservatively (follow-up group). Bethesda System for Reporting Thyroid Cytopathology class III was divided into four subcategories on the basis of cytomorphological features (III-1, III-2, III-3, III-4). Clinical risk was defined on the basis of histological, cytological, and ultrasound data. Malignancy was higher in Bethesda System for Reporting Thyroid Cytopathology class III vs. Bethesda System for Reporting Thyroid Cytopathology class IV (34.4 vs. 26.2 %; p < 0.01). Papillary thyroid carcinoma was the most frequent cancer in each Bethesda System for Reporting Thyroid Cytopathology class (35 %). BRAFV600E diagnostic accuracy was 87 %. Repeated FNAB reclassified as benign nearly 40 % of nodules, selecting patients where surgery could be spared. Significant nodule growth occurred in 13.7 % of nodules, belonging mostly to Bethesda System for Reporting Thyroid Cytopathology class III-2 and Bethesda System for Reporting Thyroid Cytopathology class IV. Overall clinical risk was higher in Bethesda System for Reporting Thyroid Cytopathology III-1, III-4, and IV classes. We propose a differential management of Bethesda System for Reporting Thyroid Cytopathology III and IV classes and related subcategories: surgery may be indicated in Bethesda System for Reporting Thyroid Cytopathology class III-1, III-4, and IV; a conservative follow-up avoiding repeated FNAB may be appropriated in class III-3, while repeated FNAB may be useful in class III-2.

Keywords

Thyroid nodule management Indeterminate thyroid nodule Cytological sub-categories Thyroid nodule clinical risk 

Notes

Acknowledgments

This work was supported by grants from the Italian Ministry of Education, Research and University (FIRB RBAP11884 M, RBAP1153LS), Associazione Italiana per la Ricerca sul Cancro (AIRC) in collaboration with “Laboratorio in rete del Tecnopolo Tecnologie delle terapie avanzate” (LTTA) of the University of Ferrara.

Compliance with ethical standards

Conflict of interest

MCZ has received consultant fees from Novartis and Genzyme. EdU has received consultant fees from Novartis and grant support from Sanofi. The remaining authors declare that they have no conflict of interest.

References

  1. 1.
    B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26, 1–133 (2016). doi: 10.1089/thy.2015.0020
  2. 2.
    E.S. Cibas, S.Z. Ali, NCI Thyroid FNA state of the science conference. The Bethesda System for Reporting Thyroid Cytopathology. Am. J. Clin. Pathol. 132, 658–665 (2009). doi: 10.1309/AJCPPHLWMI3JV4LA
  3. 3.
    H. Gharib, E. Papini, R. Paschke, D.S. Duick, R. Valcavi, L. Hegedüs, P. Vitti, AACE/AME/ETA task force on thyroid nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr. Pract. 16, 468–475 (2010)CrossRefPubMedGoogle Scholar
  4. 4.
    N.P. Ohori, K.E. Schoedel, Variability in the atypia of undetermined significance/follicular lesion of undetermined significance diagnosis in the Bethesda System for Reporting Thyroid Cytopathology: sources and recommendations. Acta Cytol. 55, 492–498 (2011). doi: 10.1159/000334218
  5. 5.
    H.H. Wu, C. Rose, T.M. Elsheikh, The Bethesda System for Reporting Thyroid Cytopathology: an experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy. Diagn. Cytopathol. 40, 399–403 (2012). doi: 10.1002/dc.21754
  6. 6.
    J.H. Park, S.O. Yoon, E.J. Son, H.M. Kim, J.H. Nahm, S. Hong, Incidence and malignancy rates of diagnoses in the Bethesda System for Reporting Thyroid Aspiration Cytology: an institutional experience. Korean J. Pathol. 48, 133–139 (2014). doi:10.4132Google Scholar
  7. 7.
    M. Bongiovanni, J.F. Krane, E.S. Cibas, W.C. Faquin, The atypical thyroid fine-needle aspiration: past, present, and future. Cancer Cytopathol. 120, 73–86 (2012). doi: 10.1002/cncy.20178
  8. 8.
    H.J. Park, J.H. Moon, C.K. Yom, K.H. Kim, J.Y. Choi, S.I. Choi, S.H. Ahn, W.J. Jeong, W.W. Lee, S.Y. Park, Thyroid “atypia of undetermined significance” with nuclear atypia has high rates of malignancy and BRAF mutation. Cancer Cytopathol. 122, 512–520 (2014). doi: 10.1002/cncy.21411
  9. 9.
    A.A. Renshaw, Should “atypical follicular cells” in thyroid fine-needle aspirates be subclassified?. Cancer Cytopathol. 118(4), 186–189 (2010). doi: 10.1002/cncy.20091 CrossRefPubMedGoogle Scholar
  10. 10.
    A.A. Renshaw, Subclassification of atypical cells of undetermined significance in direct smears of fine-needle aspirations of the thyroid: distinct patterns and associated risk of malignancy. Cancer Cytopathol. 119, 322–327 (2011). doi: 10.1002/cncy.20154
  11. 11.
    R.S. Mehta, S.E. Carty, N.P. Ohori, S.P. Hodak, C. Coyne, S.O. LeBeau, M.E. Tublin, M.T. Stang, J.T. Johnson, K.L. McCoy, M.N. Nikiforova, Y.E. Nikiforov, L. Yip, Nodule size is an independent predictor of malignancy in mutation-negative nodules with follicular lesion of undetermined significance cytology. Surgery. 154, 730–738 (2013). doi: 10.1016/j.surg.2013.05.015
  12. 12.
    S.M. Khoncarly, S.W. Tamarkin, C.R. McHenry, Can ultrasound be used to predict malignancy in patients with a thyroid nodule and an indeterminate fine-needle aspiration biopsy? Surgery. 56, 967–970 (2014). doi: 10.1016/j.surg.2014.06.043
  13. 13.
    W.S. Yoo, H.S. Choi, S.W. Cho, J.H. Moon, K.W. Kim, H.J. Park, S.Y. Park, S.I. Choi, S.H. Choi, S. Lim, K.H. Yi, J. Park do, H.C. Jang, Y.J. Park, The role of ultrasound findings in the management of thyroid nodules with atypia or follicular lesions of undetermined significance. Clin. Endocrinol. (Oxf.). 80, 735–742 (2014). doi: 10.1111/cen.12348
  14. 14.
    Y.E. Nikiforov, S.E. Carty, S.I. Chiosea, C. Coyne, U. Duvvuri, R.L. Ferris, W.E. Gooding, S.P. Hodak, S.O. LeBeau, N.P. Ohori, R.R. Seethala, M.E. Tublin, L. Yip, M.N. Nikiforova, Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 120, 3627–3634 (2014). doi: 10.1002/cncr.29038
  15. 15.
    M. Rossi, M. Buratto, S. Bruni, C. Filieri, F. Tagliati, G. Trasforini, R. Rossi, M.D. Beccati, E.C. Degli Uberti, M.C. Zatelli, Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study. J. Clin. Endocrinol. Metab. 97, 2354–2361 (2012). doi: 10.1210/jc.2011-3494
  16. 16.
    M. Rossi, M. Buratto, F. Tagliati, R. Rossi, S. Lupo, G. Trasforini, G. Lanza, P. Franceschetti, S. Bruni, E. Degli Uberti, M.C. Zatelli, Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer. Thyroid. 25, 221–228 (2015). doi: 10.1089/thy.2014.0338
  17. 17.
    V.F. Brauer, P. Eder, K. Miehle, T.D. Wiesner, H. Hasenclever, R. Paschke, Interobserver variation for ultrasound determination of thyroid nodule volumes. Thyroid 15, 1169–1175 (2005)CrossRefPubMedGoogle Scholar
  18. 18.
    M.C. Zatelli, G. Trasforini, S. Leoni, G. Frigato, M. Buratto, F. Tagliati, R. Rossi, L. Cavazzini, E. Roti, E.C. degli Uberti, BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur. J. Endocrinol. 161, 467–473 (2009). doi: 10.1530/EJE-09-0353
  19. 19.
    E.S. Cibas, Z.W. Baloch, G. Fellegara, V.A. LiVolsi, S.S. Raab, J. Rosai, J. Diggans, L. Friedman, G.C. Kennedy, R.T. Kloos, R.B. Lanman, S.J. Mandel, N. Sindy, D.L. Steward, M.A. Zeiger, B.R. Haugen, E.K. Alexander, A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann. Intern. Med. 159, 325–332 (2013). doi: 10.7326/0003-4819-159-5-201309030-00006
  20. 20.
    R. Gerhard, G. da Cunha Santos, Inter- and intraobserver reproducibility of thyroid fine needle aspiration cytology: an analysis of discrepant cases. Cytopathology 18, 105–111 (2007)CrossRefPubMedGoogle Scholar
  21. 21.
    A. Mathur, A. Najafian, E.B. Schneider, M.A. Zeiger, M.T. Olson, Malignancy risk and reproducibility associated with atypia of undetermined significance on thyroid cytology. Surgery. 156, 1471–1476 (2014). doi: 10.1016/j.surg.2014.08.026
  22. 22.
    M.T. Olson, T. Boonyaarunnate, P. Aragon Han, C.B. Umbricht, S.Z. Ali, M.A. Zeiger, A tertiary center’s experience with second review of 3885 thyroid cytopathology specimens. J. Clin. Endocrinol. Metab. 98, 1450–1457 (2013). doi: 10.1210/jc.2012-3898
  23. 23.
    C. Durante, G. Costante, G. Lucisano, R. Bruno, D. Meringolo, A. Paciaroni, E. Puxeddu, M. Torlontano, S. Tumino, M. Attard, L. Lamartina, A. Nicolucci, S. Filetti, The natural history of benign thyroid nodules. J. Am. Med. Assoc. 313, 926–935 (2015). doi: 10.1001/jama.2015.0956
  24. 24.
    H. Nakamura, M. Hirokawa, H. Ota, M. Kihara, A. Miya, A. Miyauchi Is an increase in thyroid nodule volume a risk factor for malignancy? Thyroid. 25, 804–811 (2015). doi: 10.1089/thy.2014.0567
  25. 25.
    E. Bandeira-Echtler, K. Bergerhoff, B. Richter, Levothyroxine or minimally invasive therapies for benign thyroid nodules. Cochrane Database Syst. Rev. Jun 18;(6):CD004098 (2014). doi: 10.1002/14651858
  26. 26.
    J.T. Broome, C.C. Solorzano, The impact of atypia/follicular lesion of undetermined significance on the rate of malignancy in thyroid fine-needle aspiration: evaluation of the Bethesda System for Reporting Thyroid Cytopathology. Surgery. 150, 1234–1241 (2011). doi: 10.1016/j.surg.2011.09.006
  27. 27.
    W.C. Faquin, Z.W. Baloch, Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to National Cancer Institute (NCI) recommendations. Diagn. Cytopathol. 38, 731–739 (2010). doi: 10.1002/dc.21292
  28. 28.
    Y.E. Nikiforov, S.E. Carty, S.I. Chiosea, C. Coyne, U. Duvvuri, R.L. Ferris, W.E. Gooding, S.O. LeBeau, N.P. Ohori, R.R. Seethala, M.E. Tublin, L. Yip, M.N. Nikiforova, Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology. Thyroid. 25, 1217–1223 (2015). doi: 10.1089/thy.2015.0305
  29. 29.
    S. Beaudenon-Huibregtse, E.K. Alexander, R.B. Guttler, J.M. Hershman, V. Babu, T.C. Blevins, P. Moore, B. Andruss, E. Labourier, Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. Thyroid. 24, 1479–1487 (2014). doi: 10.1089/thy.2013.0640
  30. 30.
    R. Gerhard, S.L. Boerner, Evaluation of indeterminate thyroid cytology by second-opinion diagnosis or repeat fine-needle aspiration: which is the best approach? Acta Cytol. 59, 43–50 (2015). doi: 10.1159/000369332
  31. 31.
    R. Gerhard, S.L. Boerner, The value of second opinion in thyroid cytology: a review. Cancer Cytopathol. 122, 611–619 (2014). doi: 10.1002/cncy.21436
  32. 32.
    A.A. Renshaw, Does a repeated benign aspirate change the risk of malignancy after an initial atypical thyroid fine-needle aspiration? Am. J. Clin. Pathol. 134, 788–792 (2010). doi: 10.1309/AJCPRA9Y2XQVFOFV
  33. 33.
    A. Frasoldati, R. Valcavi, Challenges in neck ultrasonography: lymphadenopathy and parathyroid glands. Endocr. Pract. 10(3), 261–268 (2004)CrossRefPubMedGoogle Scholar
  34. 34.
    M. Bongiovanni, A. Spitale, W.C. Faquin, L. Mazzucchelli, Z.W. Baloch, The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol. 56, 333–339 (2012). doi: 10.1159/000339959

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Martina Rossi
    • 1
    • 2
  • Sabrina Lupo
    • 1
  • Roberta Rossi
    • 2
  • Paola Franceschetti
    • 2
  • Giorgio Trasforini
    • 2
  • Stefania Bruni
    • 2
  • Federico Tagliati
    • 1
    • 2
  • Mattia Buratto
    • 1
  • Giovanni Lanza
    • 3
  • Luca Damiani
    • 1
  • Ettore degli Uberti
    • 1
    • 2
  • Maria Chiara Zatelli
    • 1
    • 2
    Email author return OK on get
  1. 1.Section of Endocrinology & Internal Medicine, Department of Medical SciencesUniversity of FerraraFerraraItaly
  2. 2.Endocrinology UnitAzienda Ospedaliero-Universitaria di FerraraFerraraItaly
  3. 3.Section of Pathology and Biomolecular Diagnostics, Department of Morphology, Surgery and Experimental MedicineUniversity of FerraraFerraraItaly

Personalised recommendations